Interim Results From the PROACT Randomized FDA IDE Trial

Reduced Anticoagulation After Mechanical Aortic Valve Replacement Narrated slide presentation from The American Association for Thoracic Surgery Annual Meeting 2013, Minneapolis, Minnesota, USA, on May 6, 2013

ISPOR Meeting Presentation

Economic Model of the Life-time Cost Impact of Heart Valve Prosthetic Choice Life-time costs savings of choosing an On-X® Prosthetic Heart Valve with no risk of re-operation compared to a stented tissue valve replaced with a transcatheter valve is estimated at $376,000 AUSTIN, TX — May 21, 2013 — On-X® Life Technologies, Inc. (On-X LTI) […]

Enrollment Completed

Low-Risk Aortic and Mitral Patient Groups for On-X Prosthetic Heart Valve Anticoagulation Clinical Study Low-risk aortic valve patients are maintained with aspirin and clopidogrel only AUSTIN, TX – May 7, 2013 – On-X® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the Low-Risk Aortic Valve and Mitral Valve Patient Groups has been completed. […]

AATS Report: PROACT

Prospective Randomized On-X Heart Valve Clinical Trial Provides Evidence of Reduced Complications On-X aortic valve trial is the first to formally study patients maintained at levels of anticoagulation below those currently recommended by professional society guidelines, helping to lessen anticoagulation-related complications AUSTIN, TX – May 6, 2013 – On-X® Life Technologies, Inc. (On-X LTI) announced […]

On-X LTI Receives FDA Approval

On-X Heart Valve with Anatomic Shaped Sewing Ring The On-X Aortic Heart Valve with an anatomic shaped sewing ring matches the shape of the native aortic annulus and helps prevent flattening and distortion AUSTIN, TX – February 26, 2013 – On-X® Life Technologies, Inc. (On-X LTI) announced today that it has received approval from the […]

The On-X® Heart Valve Compares Favorably to Tissue Valves

Results from a study comparing the On-X mechanical heart valve to tissue valves Matched Patient Groups in Reduced Anticoagulation Trial Provide Evidence of Improved Mortality Rate for Patients AUSTIN, TX – May 23, 2012 – On-X® Life Technologies, Inc. (On-X LTI) announced today that results from a study comparing the On-X mechanical heart valve to […]

Enrollment Objective Achieved

FDA-approved PROACT (Prospective Randomized On-X Anticoagulation Trial) expects to complete enrollment for all patient groups in 2011 AUSTIN, TX — July 26, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that the enrollment objective for the Low-Risk Aortic Valve Patient Group has been achieved. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was […]

On-X Heart Valve PROACT Trial Report

On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence toward Maintaining Patients with Less Warfarin Preliminary Results of FDA-Approved PROACT Trial show the On-X® Valve continues to demonstrate tolerance of low INR seen in worldwide studies AUSTIN, TX — April 06, 2011 — On-X® Life Technologies, Inc. announced today that preliminary results from a Food […]

On-X Heart Valve Shows Safety with Reduced Blood Thinners

On-X Heart Valve Shows Safety with Reduced Blood Thinners Early Data Reported From Large FDA IDE Clinical Trial is Encouraging New Orleans, LA — April 5, 2011 – Patients with a mechanical heart valve need lifelong treatment with blood-thinning drugs like warfarin − anticoagulants that prevent blood from clotting on the man-made material but also […]

Clinical Update Thirty-Four: On-X Heart Valve Outperform

On-X Heart Valves outperform tissue valves in a matched study On-X® Prosthetic Heart Valve patients in a prospective study matched to patients implanted with tissue valves showed a definite advantage in mortality.1   The On-X® Prosthetic Heart Valve provides lower mortality Study results reported at the recent Society of Thoracic Surgeons (STS) meeting in San […]

Onxlti Responsive Menu
Menu